Efficacy and Safety of Non-Ablative Dual Wavelength Diode Laser Therapy for Genitourinary Syndrome of Menopause: A Single-Center Prospective Study
Advances in Therapy · 2024
DOI: 10.1007/s12325-024-03004-7 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Advances in Therapy, 2024. Verfasst von Salvatore Giovanni Vitale und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecology and Obstetrics, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy. Hauptthemen laut MEDLINE: Lasers, Semiconductor, Quality of Life. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: This study evaluates the efficacy and safety of non-ablative diode laser therapy for genitourinary syndrome of menopause (GSM) in post-menopausal women unable to use hormonal therapies. METHODS: A pilot prospective study was conducted from September 2023 to April 2024, involving 22 post-menopausal women aged 45-73 years. Participants underwent three sessions of diode laser treatment with the Leonardo® dual-wavelength Diode laser. Assessments were made at baseline, 3 months, and 6 months post-treatment. Main outcome measures included Visual Analog Scale (VAS) scores for GSM symptoms, Vaginal Health Index Score (VHIS), and sexual function evaluated using the Female Sexual Function Index (FSFI-6), Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12), and Sexual Quality of Life-Female (SQOL-F) questionnaire. RESULTS: Significant improvements were observed in VHIS, increasing from 12 to 19.27 at 6 months (p < 0.001). GSM symptoms improved significantly: vaginal dryness scores decreased from 7.72 ± 2.37 to 3.72 ± 2.53, burning sensation scores dropped from 6.00 ± 3.22 to 1.90 ± 1.81, and dyspareunia scores reduced from 8.09 ± 2.11 to 3.90 ± 2.58 (all p < 0.016). Sexual function improved, indicated by FSFI-6 scores increasing from 12.27 ± 7.29 to 19.30 ± 6.24 (p < 0.016) and SQOL-F scores rising from 63.18 ± 22.93 to 71.45 ± 23.31. No adverse events were reported. CONCLUSION: Non-ablative diode laser therapy is effective and safe for managing GSM symptoms in post-menopausal women, offering significant symptom relief and enhancing sexual health without serious side effects. Further research with a larger cohort and extended follow-up is needed to confirm these findings. TRIAL REGISTRATION: Clinical Trials ID NCT06503003.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gynecology and Obstetrics, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.
- Division of Gynecology and Obstetrics, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy. saponara.stef@gmail.com.
ORCID-Profile: Salvatore Giovanni Vitale, Stefania Saponara
Zitieren
APA
Vitale, S. G., Saponara, S., Succu, A. G., Sicilia, G., Martsidis, K., D'Alterio, M. N., & Angioni, S. (2024). Efficacy and Safety of Non-Ablative Dual Wavelength Diode Laser Therapy for Genitourinary Syndrome of Menopause: A Single-Center Prospective Study. Advances in Therapy. https://doi.org/10.1007/s12325-024-03004-7
Vancouver
Vitale SG, Saponara S, Succu AG, Sicilia G, Martsidis K, D'Alterio MN, et al. Efficacy and Safety of Non-Ablative Dual Wavelength Diode Laser Therapy for Genitourinary Syndrome of Menopause: A Single-Center Prospective Study. Advances in Therapy. 2024. doi:10.1007/s12325-024-03004-7
BibTeX
@article{Vitale2024,
author = {Vitale, Salvatore Giovanni and Saponara, Stefania and Succu, Antonio Giuseppe and Sicilia, Gilda and Martsidis, Konstantinos and D'Alterio, Maurizio Nicola and Angioni, Stefano},
title = {Efficacy and Safety of Non-Ablative Dual Wavelength Diode Laser Therapy for Genitourinary Syndrome of Menopause: A Single-Center Prospective Study},
journal = {Advances in Therapy},
year = {2024},
doi = {10.1007/s12325-024-03004-7}
}
EUVIMED